Debt-to-equity of BeOne Medicines Ltd. from 30 Sep 2016 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
BeOne Medicines Ltd. quarterly Debt-to-equity in % history and change rate from 30 Sep 2016 to 31 Dec 2025.
  • BeOne Medicines Ltd. Debt-to-equity for the quarter ending 31 Dec 2025 was 77%, a 8.4% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

BeOne Medicines Ltd. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 77% +6% +8.4% 31 Dec 2025
Q3 2025 74% +6.4% +9.4% 30 Sep 2025
Q2 2025 70% +8.3% +13% 30 Jun 2025
Q1 2025 71% +14% +24% 31 Mar 2025
Q4 2024 71% +21% +40% 31 Dec 2024
Q3 2024 68% +22% +46% 30 Sep 2024
Q2 2024 62% +16% +35% 30 Jun 2024
Q1 2024 57% +14% +32% 31 Mar 2024
Q4 2023 51% +9.5% +23% 31 Dec 2023
Q3 2023 46% +6.6% +16% 30 Sep 2023
Q2 2023 46% +4.1% +9.9% 30 Jun 2023
Q1 2023 43% -1.3% -2.8% 31 Mar 2023
Q4 2022 41% -5.8% -12% 31 Dec 2022
Q3 2022 40% -9.9% -20% 30 Sep 2022
Q2 2022 42% -0.97% -2.3% 30 Jun 2022
Q1 2022 44% +2.4% +5.8% 31 Mar 2022
Q4 2021 47% +5.7% +14% 31 Dec 2021
Q3 2021 50% +7.4% +17% 30 Sep 2021
Q2 2021 43% -7.6% -15% 30 Jun 2021
Q1 2021 42% -4% -8.7% 31 Mar 2021
Q4 2020 41% -2% -4.7% 31 Dec 2020
Q3 2020 42% +6.7% +19% 30 Sep 2020
Q2 2020 50% +20% +69% 30 Jun 2020
Q1 2020 46% +17% +58% 31 Mar 2020
Q4 2019 43% +16% +60% 31 Dec 2019
Q3 2019 36% +5.7% +19% 30 Sep 2019
Q2 2019 30% -6% -17% 30 Jun 2019
Q1 2019 29% -11% -27% 31 Mar 2019
Q4 2018 27% -19% -41% 31 Dec 2018
Q3 2018 30% -6.5% -18% 30 Sep 2018
Q2 2018 36% +2.1% +6.2% 30 Jun 2018
Q1 2018 40% +21% +113% 31 Mar 2018
Q4 2017 46% +31% +202% 31 Dec 2017
Q3 2017 37% +10% +40% 30 Sep 2017
Q2 2017 34% 30 Jun 2017
Q1 2017 19% 31 Mar 2017
Q4 2016 15% 31 Dec 2016
Q3 2016 26% 30 Sep 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.